The NSABP Cancer Control Network (CGOP) Program proposed in this application will increase the number of patients receiving state of the art cancer care by extending clinical trial participation further into the community setting. The current proposal will continue and expand the ongoing program, which began in 1978, through twenty-five geographically dispersed networks, five of which are new to the program. The specific program objectives include: 1) introduce and promote patient protocol management in the community setting; 2) develop and maintain systems of support and education for the community physicians; 3) institute and maintain procedures that ensure the quality of care. The typical cancer control network consists of a major medical center and its cancer control satellites, which are either community hospitals or physician groups practicing in a community setting. The community physicians are invited to participate in NSABP protocols, provided that all institutional and physician eligibility criteria have been met. To be classified as a community physician, the physician's primary appointment must be at a satellite facility of the network institution and must have responsibility for at least one aspect of community patient care: surgery, treatment, or follow-up. The mechanism by which the community physician is recruited depends upon the organization of the particular cancer control network, but the physician's participation is facilitated through the provision of appropriate educational and support services. All components of the NSABP quality assurance program apply equally to community and non-community patients: pathology review, surgery review, radiation therapy review, toxicity monitoring, medical review for eligibility and treatment failure, quality control of estrogen and progesterone receptor assays, drug accountability, medical record audits, institutional evaluations, monitoring of forms submission, and quality control in data processing. These procedures assure high quality protocol participation while the Cancer Control Network activities facilitate the accrual of community patients into high quality NSABP breast and colorectal cancer protocols.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA039086-07
Application #
3558259
Study Section
Special Emphasis Panel (SRC (44))
Project Start
1985-02-01
Project End
1992-01-31
Budget Start
1990-12-01
Budget End
1992-01-31
Support Year
7
Fiscal Year
1991
Total Cost
Indirect Cost
Name
University of Pittsburgh
Department
Type
Schools of Medicine
DUNS #
053785812
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Fisher, E R; Anderson, S; Tan-Chiu, E et al. (2001) Fifteen-year prognostic discriminants for invasive breast carcinoma: National Surgical Adjuvant Breast and Bowel Project Protocol-06. Cancer 91:1679-87
Mamounas, E; Wieand, S; Wolmark, N et al. (1999) Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04) J Clin Oncol 17:1349-55
Wolmark, N; Rockette, H; Mamounas, E et al. (1999) Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast J Clin Oncol 17:3553-9
Fisher, E R; Dignam, J; Tan-Chiu, E et al. (1999) Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17: intraductal carcinoma. Cancer 86:429-38
Fisher, B; Dignam, J; Wolmark, N et al. (1998) Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol 16:441-52
Dignam, J J; Bryant, J; Wieand, H S et al. (1998) Early stopping of a clinical trial when there is evidence of no treatment benefit: protocol B-14 of the National Surgical Adjuvant Breast and Bowel Project. Control Clin Trials 19:575-88
Fisher, B; Bryant, J; Wolmark, N et al. (1998) Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16:2672-85
Fisher, B; Brown, A; Mamounas, E et al. (1997) Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15:2483-93
Fisher, E R (1997) Pathobiological considerations relating to the treatment of intraductal carcinoma (ductal carcinoma in situ) of the breast. CA Cancer J Clin 47:52-64
Dignam, J J; Redmond, C K; Fisher, B et al. (1997) Prognosis among African-American women and white women with lymph node negative breast carcinoma: findings from two randomized clinical trials of the National Surgical Adjuvant Breast and Bowel Project (NSABP). Cancer 80:80-90

Showing the most recent 10 out of 33 publications